Merck Press Releases - EIN Presswire - Press Release Distribution Service

Published on June 11, 2015 - 12:22 GMT

Merck Launches New Program That Encourages Women to “Rule the Real Talk” and Prioritize Their Sexual Health

KENILWORTH, N.J.-– Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today the results of a recent on-line survey about women’s views on relationships and sex, which found that women are less assertive about initiating …

Distribution channels: Companies

Published on June 10, 2015 - 13:08 GMT

Merck and Samsung Bioepis Announce Pivotal Phase 3 Studies for Investigational Biosimilars SB4, Enbrel (Etanercept), and SB2, ...

KENILWORTH, N.J. & SEOUL, South Korea--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Samsung Bioepis Co., Ltd. today announced that pivotal Phase 3 clinical studies of SB4, an investigational biosimilar of …

Distribution channels: Companies

Published on June 8, 2015 - 20:31 GMT

TECOS, Merck’s Cardiovascular Safety Trial of JANUVIA (sitagliptin), Met Primary Endpoint in Patients with Type 2 Diabetes

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the primary results of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS), a placebo-controlled study of the …

Distribution channels: Companies

Published on June 3, 2015 - 21:08 GMT

Results from Investigational IMPROVE-IT Study of VYTORIN® (ezetimibe and simvastatin) Published in the New England Journal of ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the New England Journal of Medicine published the results of the IMPROVE-IT trial, an investigational study comparing treatment …

Distribution channels: Companies

Published on June 1, 2015 - 21:03 GMT

FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, in ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for Merck …

Distribution channels: Companies

Published on June 1, 2015 - 12:38 GMT

Merck and Dynavax Announce New Collaboration Investigating the Combination of Immuno-Oncology Therapies

KENILWORTH, N.J. & BERKELEY, Calif.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Dynavax Technologies Corporation (Nasdaq: DVAX) today announced they have entered into two clinical trial collaboration …

Distribution channels: Companies

Published on June 1, 2015 - 12:07 GMT

Findings Presented at 2015 ASCO Annual Meeting Add to Breadth of KEYTRUDA® (pembrolizumab) Data; Anti-Tumor Activity Now ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the first-time presentation of findings investigating the use of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in …

Distribution channels: Companies

Published on May 30, 2015 - 18:04 GMT

TESARO and Merck to Collaborate on a Combination Study of Niraparib and KEYTRUDA® (pembrolizumab)

WALTHAM, Mass., and KENILWORTH, N.J., May 30, 2015 – TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced a collaboration to evaluate the …

Distribution channels: Companies

Published on May 29, 2015 - 18:08 GMT

First Study Evaluating DNA Mismatch Repair as Genetic Guide for Immunotherapy Treatment with Merck’s KEYTRUDA® (pembrolizumab) ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from the first study evaluating the correlation of benefit with an immunotherapy based on DNA mismatch repair (MMR) deficiency, …

Distribution channels: Companies

Published on May 29, 2015 - 18:08 GMT

New Findings Show Durable Anti-Tumor Activity with KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, in Patients with Advanced ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced new investigational data evaluating KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, as a monotherapy from the KEYNOTE-012 …

Distribution channels: Companies

Published on May 29, 2015 - 12:40 GMT

AMGEN AND MERCK ANNOUNCE EXPANSION OF COLLABORATION TO SUPPORT STUDIES OF TALIMOGENE LAHERPAREPVEC IN COMBINATION WITH KEYTRUDA® (...

THOUSAND OAKS, Calif. and KENILWORTH, N.J., - May 29, 2015 – Amgen (NASDAQ: AMGN) and Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, today announced an expanded collaboration to evaluate the efficacy and safety of talimogene laherparepvec, …

Distribution channels: Companies

Published on May 28, 2015 - 20:57 GMT

Merck Submits U.S. New Drug Application for Grazoprevir/Elbasvir, an Investigational Once-Daily, Single Tablet Combination Therapy,...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the company has submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for grazoprevir/elbasvir (100mg/ …

Distribution channels: Companies

Published on May 28, 2015 - 12:34 GMT

Merck and NanoString Announce Clinical Research Collaboration to Develop an Immune-Related Gene Expression Assay for Use in the ...

KENILWORTH, N.J. & SEATTLE--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and NanoString Technologies, Inc. (NASDAQ:NSTG) today announced a clinical research collaboration to develop an assay that will optimize …

Distribution channels: Companies

Published on May 26, 2015 - 17:58 GMT

Merck Announces Third-Quarter 2015 Dividend

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.45 per share of the company’s common stock for the third quarter of …

Distribution channels: Companies

Published on May 22, 2015 - 11:38 GMT

Merck Receives Positive CHMP Opinion for KEYTRUDA® (pembrolizumab) for the Treatment of Advanced Melanoma

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion …

Distribution channels: Companies

Published on May 13, 2015 - 21:32 GMT

2015 ASCO Annual Meeting: New Data in 10 Different Cancers from Merck’s Rapidly Expanding Immuno-Oncology Research Program for ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that new investigational data in 10 different types of cancer from the company’s immuno-oncology development program evaluating its anti …

Distribution channels: Companies

Published on May 7, 2015 - 12:51 GMT

Plexxikon and Merck to Collaborate on Combination Study Evaluating Investigational Immuno-oncology Regimen

BERKELEY, Calif., and KENILWORTH, N.J. — May 7, 2015 – Plexxikon Inc., a member of Daiichi Sankyo Group, and Merck (NYSE:MRK), known as MSD outside the US and Canada, through a subsidiary, today announced a collaborative clinical trial that will evaluate …

Distribution channels: Companies

Published on April 28, 2015 - 11:21 GMT

Merck Announces First-Quarter 2015 Financial Results

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2015. First Quarter $ in millions, except EPS amounts 2015 2014 Sales $9,425 $10, …

Distribution channels: Companies

Published on April 27, 2015 - 22:36 GMT

Merck Announces Publication of Pivotal Data from Phase 3 Clinical Studies of ZERBAXA™ (Ceftolozane/Tazobactam) in The Lancet and ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that The Lancet and Clinical Infectious Diseases have published online the results from the pivotal Phase 3 clinical studies of ZERBAXA™ …

Distribution channels: Companies

Published on April 27, 2015 - 21:19 GMT

Merck Announces the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) Met Primary Endpoint

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) of Merck’s DPP-4 inhibitor, JANUVIA® (sitagliptin), achieved …

Distribution channels: Companies